Natera president Solomon Moshkevich sells over $5.9m in shares

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold shares of the company's stock, amounting to approximately $5.92 million, as reported in a filing with the Securities and Exchange Commission. The transactions took place on two separate days, September 1 and September 2, 2026. On September 1, Moshkevich sold a total of 2,500 shares at varying prices, ranging from $319.2850 to $326.894 per share.

The following day, he sold an additional 15,160 shares at a price of $326.894 per share. Throughout this period, the prices received for the sold shares ranged from $319.7582 to $326.894. This sale occurred as Natera's stock hovers close to its 52-week high of $343.18, having generated a remarkable 97% return over the past year.

According to InvestingPro analysis, the stock's current valuation appears overvalued relative to its estimated fair value, placing it among the most overvalued stocks tracked by the platform. Moshkevich's transactions on September 1 were executed under a pre-established Rule 10b5-1 trading plan, which he established on November 26, 2024.

The sale on September 2 was specifically intended to address tax withholding and remittance obligations associated with the vesting of restricted stock units (RSUs), as per a Rule 10b5-1(c) instruction. Post these transactions, Moshkevich retains a direct ownership of 110,859 shares of Natera common stock. The company, valued at $47.2 billion, has demonstrated robust momentum with a revenue growth of 38% in the last twelve months.

Investors interested in further insights about Natera can explore 13 ProTips offered by InvestingPro, along with comprehensive Pro Research Reports on over 1,400 US equities. Recently, Natera reported its second-quarter revenue, which exceeded market expectations significantly, with the company generating approximately $753 million, surpassing the forecasted $661.26 million.

This strong performance was driven by accelerated growth across the company's main business segments. Furthermore, Natera's management raised its full-year revenue guidance, citing record test volumes and improved margins, along with a series of regulatory wins contributing to a positive outlook. These developments were favorably received by the market, with the company's shares experiencing an increase in after-hours trading.

Investors are expected to closely monitor these positive financial indicators as Natera continues to expand its market presence.